X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES SANOFI INDIA VENUS REMEDIES/
SANOFI INDIA
 
P/E (TTM) x -954.1 31.0 - View Chart
P/BV x 0.3 5.9 4.7% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 VENUS REMEDIES   SANOFI INDIA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
SANOFI INDIA
Dec-16
VENUS REMEDIES/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs2184,560 4.8%   
Low Rs824,400 1.9%   
Sales per share (Unadj.) Rs365.61,028.5 35.5%  
Earnings per share (Unadj.) Rs1.5129.0 1.2%  
Cash flow per share (Unadj.) Rs37.9186.0 20.4%  
Dividends per share (Unadj.) Rs068.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs382.5753.6 50.8%  
Shares outstanding (eoy) m11.4423.03 49.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.44.4 9.4%   
Avg P/E ratio x101.034.7 290.7%  
P/CF ratio (eoy) x4.024.1 16.4%  
Price / Book Value ratio x0.45.9 6.6%  
Dividend payout %052.7 0.0%   
Avg Mkt Cap Rs m1,717103,174 1.7%   
No. of employees `0001.03.6 28.2%   
Total wages/salary Rs m3243,592 9.0%   
Avg. sales/employee Rs Th4,100.76,537.7 62.7%   
Avg. wages/employee Rs Th318.0991.4 32.1%   
Avg. net profit/employee Rs Th16.7819.8 2.0%   
INCOME DATA
Net Sales Rs m4,18323,686 17.7%  
Other income Rs m20708 2.8%   
Total revenues Rs m4,20324,394 17.2%   
Gross profit Rs m8125,281 15.4%  
Depreciation Rs m4171,313 31.7%   
Interest Rs m38015 2,532.0%   
Profit before tax Rs m354,661 0.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m181,691 1.1%   
Profit after tax Rs m172,970 0.6%  
Gross profit margin %19.422.3 87.0%  
Effective tax rate %51.636.3 142.1%   
Net profit margin %0.412.5 3.2%  
BALANCE SHEET DATA
Current assets Rs m2,77115,673 17.7%   
Current liabilities Rs m1,9316,678 28.9%   
Net working cap to sales %20.138.0 52.8%  
Current ratio x1.42.3 61.1%  
Inventory Days Days12576 164.6%  
Debtors Days Days5422 240.9%  
Net fixed assets Rs m5,3288,098 65.8%   
Share capital Rs m114230 49.7%   
"Free" reserves Rs m4,17717,088 24.4%   
Net worth Rs m4,37617,356 25.2%   
Long term debt Rs m1,9110-   
Total assets Rs m8,42825,400 33.2%  
Interest coverage x1.1311.7 0.4%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.9 53.2%   
Return on assets %4.711.8 40.1%  
Return on equity %0.417.1 2.3%  
Return on capital %6.626.9 24.5%  
Exports to sales %024.5 0.0%   
Imports to sales %20.528.0 73.3%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs m8586,627 13.0%   
Fx inflow Rs m07,145 0.0%   
Fx outflow Rs m8586,846 12.5%   
Net fx Rs m-858299 -287.1%   
CASH FLOW
From Operations Rs m4693,226 14.5%  
From Investments Rs m29-1,555 -1.9%  
From Financial Activity Rs m-464-1,818 25.5%  
Net Cashflow Rs m35-147 -23.5%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 0.2 14.4 1.3%  
FIIs % 0.6 14.6 4.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 10.5 632.4%  
Shareholders   20,121 15,184 132.5%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  ABBOTT INDIA  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Dull Start to the Week; Cement Stocks Tank(Closing)

Indian share markets continued to trade on a dull note in the afternoon session amid weak international markets.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

'Buy and Hold Forever' Not The Best Investing Style After All(The 5 Minute Wrapup)

Nov 9, 2017

Even Buffett didn't always Buy and Hold forever. A look at Berkshire's 1992 and 2017 portfolios will tell you the story...

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

You're Lucky You Missed Out on that IPO...(Smart Contrarian)

Nov 8, 2017

Here's how to profit from upcoming IPOs.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 20, 2017 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS